United States - English - NLM (National Library of Medicine)

merck sharp & dohme corp. - fluralaner (unii: wsh8393rm5) (fluralaner - unii:wsh8393rm5) - fluralaner 112.5 mg - bravecto kills adult fleas and is indicated for the treatment and prevention of flea infestations (ctenocephalides felis ) and the treatment and control of tick infestations [ixodes scapularis (black-legged tick), dermacentor variabilis (american dog tick), and rhipicephalus sanguineus (brown dog tick)] for 12 weeks in dogs and puppies 6 months of age and older, and weighing 4.4 pounds or greater. bravecto is also indicated for the treatment and control of amblyomma americanum (lone star tick) infestations for 8 weeks in dogs and puppies 6 months of age and older, and weighing 4.4 pounds or greater. there are no known contraindications for the use of the product.

United States - English - NLM (National Library of Medicine)

merck sharp & dohme corp. - fluralaner (unii: wsh8393rm5) (fluralaner - unii:wsh8393rm5) - fluralaner 112.5 mg - bravecto kills adult fleas and is indicated for the treatment and prevention of flea infestations (ctenocephalides felis ), and the treatment and control of tick infestations [ixodes scapularis (black-legged tick), dermacentor variabilis (american dog tick), rhipicephalus sanguineus (brown dog tick), and haemaphysalis longicornis (asian longhorned tick)] for 12 weeks in dogs and puppies 6 months of age and older, and weighing 4.4 pounds or greater. bravecto is also indicated for the treatment and control of amblyomma americanum (lone star tick) infestations for 8 weeks in dogs and puppies 6 months of age and older, and weighing 4.4 pounds or greater. there are no known contraindications for the use of the product.

United States - English - NLM (National Library of Medicine)

merck sharp & dohme corp. - fluralaner (unii: wsh8393rm5) (fluralaner - unii:wsh8393rm5) - bravecto kills adult fleas and is indicated for the treatment and prevention of flea infestations (ctenocephalides felis ) and the treatment and control of ixodes scapularis (black-legged tick) and haemaphysalis longicornis (asian longhorned tick) infestations for 12 weeks in cats and kittens 6 months of age and older, and weighing 2.6 pounds or greater. bravecto is also indicated for the treatment and control of dermacentor variabilis (american dog tick) infestations for 8 weeks in cats and kittens 6 months of age and older, and weighing 2.6 pounds or greater. there are no known contraindications for the use of the product.

United States - English - NLM (National Library of Medicine)

merck sharp & dohme - fluralaner (unii: wsh8393rm5) (fluralaner - unii:wsh8393rm5), moxidectin (unii: ngu5h31yo9) (moxidectin - unii:ngu5h31yo9) - bravecto plus is indicated for the prevention of heartworm disease caused by dirofilaria immitis and for the treatment of infections with intestinal roundworm (toxocara cati ; 4th stage larvae, immature adults and adults) and hookworm (ancylostoma tubaeforme ; 4th stage larvae, immature adults and adults). bravecto plus kills adult fleas and is indicated for the treatment and prevention of flea infestations (ctenocephalides felis ) and the treatment and control of tick infestations [ixodes scapularis (black-legged tick) and dermacentor variabilis (american dog tick)] for 2 months in cats and kittens 6 months of age and older and weighing 2.6 lb or greater. there are no known contraindications for the use of the product.

United States - English - NLM (National Library of Medicine)

merck sharp & dohme corp. - fluralaner (unii: wsh8393rm5) (fluralaner - unii:wsh8393rm5) - bravecto 1-month kills adult fleas and is indicated for the treatment and prevention of flea infestations (ctenocephalides felis ) and the treatment and control of tick infestations [ixodes scapularis (black-legged tick), dermacentor variabilis (american dog tick) and rhipicephalus sanguineus (brown dog tick)] for one month in dogs and puppies 8 weeks of age and older, and weighing 4.4 pounds or greater. bravecto 1-month is also indicated for the treatment and control of amblyomma americanum (lone star tick) infestations for one month in dogs and puppies 6 months of age and older, and weighing 4.4 pounds or greater. there are no known contraindications for the use of the product.

United States - English - NLM (National Library of Medicine)

e.r. squibb & sons, l.l.c. - pravastatin sodium (unii: 3m8608uq61) (pravastatin - unii:kxo2kt9n0g) - pravastatin sodium 20 mg - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. in hypercholesterolemic patients without clinically evident coronary heart disease (chd), pravachol (pravastatin sodium) is indicated to: in patients with clinically evident chd, pravachol is indicated to: pravachol is indicated: pravachol has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (fredrickson types i and v). hypersensitivity to any component of this medication. active liver disease or unexplained, persistent elevations of serum transaminases [see warnings and precautions (5.3) ]. atherosclerosis is a chronic process and discontinuation of lipid-lowering dru

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pravastatin sodium, quantity: 80 mg - tablet, uncoated - excipient ingredients: povidone; croscarmellose sodium; iron oxide yellow; microcrystalline cellulose; magnesium stearate; lactose monohydrate; magnesium oxide - as an adjunct to diet for the treatment of hypercholesterolemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolemia (e.g. poorly controlled diabetes mellitus, hypothyrodism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alchoholism) should be identified and treated. pravachol is indicated in patients with previous myocardial infarction including those who have normal (4.0 - 5.5 mmol/l) serum cholesterol levels. pravachol is indicated in patients with unstable angina pectoris (see clinical trials). pravachol is indicated as an adjunct to diet and lifestyle modification for the treatment of heterozygous familial hypercholesterolaemia in children and adolescent patients aged 8 years and older (see clinical trails).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pravastatin sodium, quantity: 10 mg - tablet, uncoated - excipient ingredients: magnesium stearate; iron oxide yellow; magnesium oxide; croscarmellose sodium; microcrystalline cellulose; povidone; lactose monohydrate - as an adjunct to diet for the treatment of hypercholesterolemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolemia (e.g. poorly controlled diabetes mellitus, hypothyrodism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alchoholism) should be identified and treated. pravachol is indicated in patients with previous myocardial infarction and average (normal) serum cholesterol levels (see clinical trials). indications as at 23 january 2004: as an adjunct to diet for the treatment of hypercholesterolemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolemia (e.g. poorly controlled diabetes mellitus, hypothyrodism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alchoholism) should be identified and treated. pravachol is indicated in patients with previous myocardial infarction including those who have normal (4.0 - 5.5 mmol/l) serum cholesterol levels. pravachol is indicated in patients with unstable angina pectoris (see clinical trials). pravachol is indicated as an adjunct to diet and lifestyle modification for the treatment of heterozygous familial hypercholesterolaemia in children and adolescent patients aged 8 years and older (see clinical trails).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pravastatin sodium, quantity: 20 mg - tablet, uncoated - excipient ingredients: croscarmellose sodium; magnesium stearate; povidone; microcrystalline cellulose; lactose monohydrate; iron oxide yellow; magnesium oxide - as an adjunct to diet for the treatment of hypercholesterolemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolemia (e.g. poorly controlled diabetes mellitus, hypothyrodism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alchoholism) should be identified and treated. pravachol is indicated in patients with previous myocardial infarction and average (normal) serum cholesterol levels (see clinical trials). indications as at 23 january 2004: as an adjunct to diet for the treatment of hypercholesterolemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolemia (e.g. poorly controlled diabetes mellitus, hypothyrodism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alchoholism) should be identified and treated. pravachol is indicated in patients with previous myocardial infarction including those who have normal (4.0 - 5.5 mmol/l) serum cholesterol levels. pravachol is indicated in patients with unstable angina pectoris (see clinical trials). pravachol is indicated as an adjunct to diet and lifestyle modification for the treatment of heterozygous familial hypercholesterolaemia in children and adolescent patients aged 8 years and older (see clinical trails).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pravastatin sodium, quantity: 40 mg - tablet, uncoated - excipient ingredients: croscarmellose sodium; magnesium oxide; magnesium stearate; povidone; lactose monohydrate; iron oxide yellow; microcrystalline cellulose - as an adjunct to diet for the treatment of hypercholesterolaemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolaemia (eg, poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysprotenemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. indications as at 20 august 1996: as an adjunct to diet for the treatment of hypercholesterolaemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolaemia, (e.g. poorly controlled diabetes mellitus, hypothroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. indications as at 2 march 1999: as an adjunct to diet for the treatment of hypercholesterolaemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. pravachol is indicated in patients with previous myocardial infarction and average (normal) serum cholesterol levels (see clinical trials). indications as at 4 august 1999: as an adjunct to diet for the treatment of hypercholesterolaemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. pravachol is indicated in patients with previous myocardial infarction and average (normal) serum cholesterol levels (see clinical trials). pravachol is indicated in patients with unstable angina pectoris (see clinical trials). indications as at 23 january 2004: as an adjunct to diet for the treatment of hypercholesterolemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolemia (e.g. poorly controlled diabetes mellitus, hypothyrodism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alchoholism) should be identified and treated. pravachol is indicated in patients with previous myocardial infarction including those who have normal (4.0 - 5.5 mmol/l) serum cholesterol levels. pravachol is indicated in patients with unstable angina pectoris (see clinical trials). pravachol is indicated as an adjunct to diet and lifestyle modification for the treatment of heterozygous familial hypercholesterolaemia in children and adolescent patients aged 8 years and older (see clinical trails).